Advertisement

Fulminant diabetes induced by PD-1 and PD-L1 inhibitors: what about glucose variability?

  • Lucien Marchand
  • Sophie Reffet
  • Stéphane Dalle
  • Emmanuel Disse
  • Julien Vouillarmet
  • Christine Cugnet-Anceau
  • Charles Thivolet
Short Communication
  • 37 Downloads

Keywords

Diabetes mellitus Fulminant diabetes Glucose variability Coefficient of variation for glucose Labile diabetes Flash glucose monitoring FreeStyle Libre Autoimmune diabetes Immune checkpoint inhibitors side effects Immunotherapy Programmed cell death-1 Anti-PD-1 Programmed death ligand 1 Anti-PD-L1 Beta-cell pancreatic function Alpha-cell pancreatic function Exocrine pancreatic function 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that there is no conflict of interest associated with this manuscript.

Human and animal rights

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008.

Informed consent

Informed consent was obtained from all patients for being included in the study.

References

  1. 1.
    Tassone F, Colantonio I, Gamarra E et al (2018) Nivolumab-induced fulminant type 1 diabetes (T1D): the first Italian case report with long follow-up and flash glucose monitoring. Acta diabetologica.  https://doi.org/10.1007/s00592-018-1246-4 (PubMed PMID: 30361845) CrossRefPubMedGoogle Scholar
  2. 2.
    Monnier L, Colette C, Wojtusciszyn A et al (2017) Toward defining the threshold between low and high glucose variability in diabetes. Diabetes Care 40(7):832–838 (PubMed PMID: 28039172) CrossRefGoogle Scholar
  3. 3.
    Marchand L, Reffet S, Vouillarmet J, Cugnet-Anceau C, Disse E, Thivolet C (2018) The 36% coefficient of variation for glucose proposed for separating stable and labile diabetes is clinically relevant: a continuous glucose monitoring-based study in a large population of type 1 diabetes patients. Diabetes Metab.  https://doi.org/10.1016/j.diabet.2018.05.009 (PubMed PMID: 29910090) CrossRefPubMedGoogle Scholar
  4. 4.
    Marchand L, Thivolet A, Dalle S et al (2018) Diabetes mellitus induced by PD-1 and PD-L1 inhibitors: description of pancreatic endocrine and exocrine phenotype. Acta Diabetol.  https://doi.org/10.1007/s00592-018-1234-8 (PubMed PMID: 30284618) CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Marchand L, Paulus V, Fabien N et al (2017) Nivolumab-induced acute diabetes mellitus and hypophysitis in a patient with advanced pulmonary pleomorphic carcinoma with a prolonged tumor response. J Thorac Oncol. 12(11):e182–e184 (PubMed PMID: 29074210) CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia S.r.l., part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Endocrinology and DiabetesHospices Civils de Lyon, Lyon-Sud HospitalPierre-BéniteFrance
  2. 2.Department of DermatologyHospices Civils de Lyon, Lyon-Sud HospitalPierre-BéniteFrance
  3. 3.ImmuCare (Immunology Cancer Research)Hospices Civils de LyonLyonFrance
  4. 4.Lyon 1 University, CarMeN Laboratory (INSERM U1060, INRA U1235, Université Claude Bernard Lyon1, INSA-Lyon)OullinsFrance

Personalised recommendations